\contentsline {chapter}{Acronyms}{v}{section*.4}
\contentsline {chapter}{\numberline {4}Synthetic Lethal Analysis of Gene Expression Data}{193}{chapter.4}
\contentsline {section}{\numberline {4.1}Synthetic lethal genes in breast cancer}{194}{section.4.1}
\contentsline {subsection}{\numberline {4.1.1}Synthetic lethal pathways in breast cancer}{196}{subsection.4.1.1}
\contentsline {subsection}{\numberline {4.1.2}Expression profiles of synthetic lethal partners}{197}{subsection.4.1.2}
\contentsline {subsubsection}{\numberline {4.1.2.1}Subgroup pathway analysis}{200}{subsubsection.4.1.2.1}
\contentsline {section}{\numberline {4.2}Comparison of synthetic lethal gene candidates}{203}{section.4.2}
\contentsline {subsection}{\numberline {4.2.1}Comparison with siRNA screen candidates}{203}{subsection.4.2.1}
\contentsline {subsubsection}{\numberline {4.2.1.1}Comparison with correlation}{204}{subsubsection.4.2.1.1}
\contentsline {subsubsection}{\numberline {4.2.1.2}Comparison with viability}{206}{subsubsection.4.2.1.2}
\contentsline {subsubsection}{\numberline {4.2.1.3}Comparison with secondary siRNA screen candidates}{209}{subsubsection.4.2.1.3}
\contentsline {subsubsection}{\numberline {4.2.1.4}Comparison of screen at pathway level}{209}{subsubsection.4.2.1.4}
\contentsline {subsubsubsection}{\numberline {4.2.1.4.1}Resampling of genes for pathway enrichment}{211}{subsubsubsection.4.2.1.4.1}
\contentsline {section}{\numberline {4.3}Metagene Analysis}{217}{section.4.3}
\contentsline {subsection}{\numberline {4.3.1}Pathway expression}{217}{subsection.4.3.1}
\contentsline {subsection}{\numberline {4.3.2}Somatic mutation}{220}{subsection.4.3.2}
\contentsline {subsection}{\numberline {4.3.3}Mutation locus}{221}{subsection.4.3.3}
\contentsline {subsection}{\numberline {4.3.4}Synthetic lethal metagenes}{223}{subsection.4.3.4}
\contentsline {section}{\numberline {4.4}Replication in stomach cancer}{225}{section.4.4}
\contentsline {subsection}{\numberline {4.4.1}Synthetic Lethal Genes and Pathways}{225}{subsection.4.4.1}
\contentsline {subsection}{\numberline {4.4.2}Synthetic Lethal Expression Profiles}{227}{subsection.4.4.2}
\contentsline {subsection}{\numberline {4.4.3}Comparison to Primary Screen}{229}{subsection.4.4.3}
\contentsline {subsubsection}{\numberline {4.4.3.1}Resampling Analysis}{230}{subsubsection.4.4.3.1}
\contentsline {subsection}{\numberline {4.4.4}Metagene Analysis}{231}{subsection.4.4.4}
\contentsline {section}{\numberline {4.5}Global Synthetic Lethality}{231}{section.4.5}
\contentsline {subsection}{\numberline {4.5.1}Hub Genes}{232}{subsection.4.5.1}
\contentsline {subsection}{\numberline {4.5.2}Hub Pathways}{234}{subsection.4.5.2}
\contentsline {section}{\numberline {4.6}Replication in cell line encyclopaedia}{235}{section.4.6}
\contentsline {section}{\numberline {4.7}Discussion}{238}{section.4.7}
\contentsline {subsection}{\numberline {4.7.1}Strengths of the SLIPT Methodology}{238}{subsection.4.7.1}
\contentsline {subsection}{\numberline {4.7.2}Syntheic Lethal Pathways for E-cadherin}{239}{subsection.4.7.2}
\contentsline {subsection}{\numberline {4.7.3}Replication and Validation}{241}{subsection.4.7.3}
\contentsline {subsubsection}{\numberline {4.7.3.1}Integration with siRNA Screening}{241}{subsubsection.4.7.3.1}
\contentsline {subsubsection}{\numberline {4.7.3.2}Replication across Tissues and Cell lines}{242}{subsubsection.4.7.3.2}
\contentsline {section}{\numberline {4.8}Summary}{242}{section.4.8}
\contentsline {paragraph}{Aims}{244}{section*.39}
\contentsline {paragraph}{Summary}{244}{section*.40}
\contentsline {chapter}{\hbox to\@tempdima {\hfil }References}{400}{section*.40}
